These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28010185)

  • 1. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
    Spindler KG
    Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.
    Berger AW; Schwerdel D; Welz H; Marienfeld R; Schmidt SA; Kleger A; Ettrich TJ; Seufferlein T
    PLoS One; 2017; 12(3):e0174308. PubMed ID: 28328955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
    Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
    Thierry AR
    Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
    Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
    PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.
    Tóth K; Barták BK; Tulassay Z; Molnár B
    Expert Rev Mol Diagn; 2016; 16(2):239-52. PubMed ID: 26652067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
    Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
    Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics and diagnostic applications of circulating cell-free DNA in colorectal cancer].
    Barták BK; Márkus E; Kalmár A; Galamb O; Szigeti K; Nagy ZB; Zsigrai S; Tulassay Z; Dank M; Igaz P; Molnár B
    Orv Hetil; 2019 Jul; 160(30):1167-1177. PubMed ID: 31327245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
    Lecomte T; Berger A; Zinzindohoué F; Micard S; Landi B; Blons H; Beaune P; Cugnenc PH; Laurent-Puig P
    Int J Cancer; 2002 Aug; 100(5):542-8. PubMed ID: 12124803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
    Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
    Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
    Herbst A; Vdovin N; Gacesa S; Ofner A; Philipp A; Nagel D; Holdt LM; Op den Winkel M; Heinemann V; Stieber P; Graeven U; Reinacher-Schick A; Arnold D; Ricard I; Mansmann U; Hegewisch-Becker S; Kolligs FT
    Int J Cancer; 2017 May; 140(9):2134-2144. PubMed ID: 28124380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
    Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.